ARVN Projected Dividend Yield
Arvinas Inc ( NASDAQ : ARVN )Arvinas is a clinical-stage biotechnology company. Co.'s investigational clinical stage programs include: ARV-471, which is an investigational orally bioavailable PROTAC protein degrader designed for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; bavdegalutamide (ARV-110), which is an investigational orally bioavailable PROTAC protein degrader designed for the treatment of men with metastatic castration-resistant prostate cancer, or mCRPC; and ARV-766, which is an investigational orally bioavailable PROTAC protein degrader designed to target AR with a different profile than bavdegalutamide, as a potential treatment for men with mCRPC. 20 YEAR PERFORMANCE RESULTS |
ARVN Dividend History Detail ARVN Dividend News ARVN Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |